RMX 1002Alternative Names: RMX-1002
Latest Information Update: 22 Feb 2019
Price : $50 *
At a glance
- Originator RMX biopharma
- Developer HaiHe Biopharma; ShangHai HaiHe Pharmaceutical
- Class Analgesics; Antineoplastics; Antirheumatics
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
- Phase I Arthritis; Familial adenomatous polyposis
Most Recent Events
- 18 Feb 2019 Haihe Pharmaceutical completes a phase I trial in Healthy volunteers in China, prior to February 2019 (HaiHe Biopharma pipeline, February 2019) .
- 18 Feb 2019 Haihe Pharmaceutical completes a phase II trial for Pain in USA, prior to February 2019 (HaiHe Biopharma pipeline, February 2019) (9260757.
- 12 Mar 2018 Phase-I clinical trials in Arthritis (In volunteers) in China (PO) (ChiCTR1800015060 )